Botanix Pharmaceuticals (ASX:BOT) Change In Inventory: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Botanix Pharmaceuticals Change In Inventory?

Botanix Pharmaceuticals ASX:BOT -5.00% Change In Inventory is A$0.00 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Botanix Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2025 was A$0.00 Mil. It means Botanix Pharmaceuticals's inventory stayed the same from Jun. 2025 to Dec. 2025 .

Botanix Pharmaceuticals's change in inventory for the fiscal year that ended in Jun. 2025 was A$0.00 Mil. It means Botanix Pharmaceuticals's inventory stayed the same from Jun. 2024 to Jun. 2025 .

Botanix Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2025 was A$27.51 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Botanix Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2025 was 852.06.

Inventory Turnover measures how fast the company turns over its inventory within a year. Botanix Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.21.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Botanix Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 1.68.

Botanix Pharmaceuticals  (ASX:BOT) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Botanix Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=27.7935/5.953*365 / 2
=852.06

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Botanix Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=5.953 / 27.7935
=0.21

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Botanix Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=27.7935 / 16.506
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals Change In Inventory Related Terms

Botanix Pharmaceuticals Change In Inventory Historical Data

* Premium members only.

The historical data trend for Botanix Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals Change In Inventory Chart

Botanix Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Botanix Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Botanix Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of A$0.00 Mil mean?
Botanix Pharmaceuticals (ASX:BOT) has a Change In Inventory of A$0.00 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Botanix Pharmaceuticals and its competitors.
Is Botanix Pharmaceuticals' Change In Inventory too high?
Botanix Pharmaceuticals' current Change In Inventory is A$0.00 Mil.
How does Botanix Pharmaceuticals' Change In Inventory compare to VRTX and REGN?
Botanix Pharmaceuticals' Change In Inventory of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Botanix Pharmaceuticals and its competitors. Botanix Pharmaceuticals's current Change In Inventory is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (ASX:BOT) has a current Change In Inventory of A$0.00 Mil. The current Change In Inventory is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Botanix Pharmaceuticals (ASX:BOT), the current Change In Inventory is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Other Exchanges BXPHF:USA
Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.